Abstract
Objective To provide diagnostic evidence and clues for patients with fever of unknown origin (FUO) through urine proteomics analysis.
Methods Urine samples of FUO were one–to–many analysed by using liquid chromatography tandem mass spectrometry(LC–MS/MS) to identify differential proteins and related biological pathways. One–to–many analysis means a comparative analysis of one sample to many controls.
Results We observed biological pathways related to fever, such as LXR/RXR activation, FXR/RXR activation and acute phase response signaling, etc., which indicates that urine can obviously distinguish disease from health status. In addition, we found that the results of each sample were different, which highlight the necessity of one–to–many analysis.
Conclusions The combined method of urine proteomics and one–to–many analysis can provide clues for FUO, and might also be applied to the exploration of any unknown disease.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
This experiment was based on the reuse of discarded samples from Laboratory Medicine, and the process did not involve any patient identity information
Funding Statement
This work was supported by the National Key Research and Development Program of China (2018YFC0910202 and2 016YFC1306300); the Fundamental Research Funds for the Central Universities (2020KJZX002); the Beijing Natural Science Foundation (7172076); the Beijing Cooperative Construction Project (110651103); the Beijing Normal University (11100704). Key Clinical Specialty Project of Beijing (2020)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All participants signed informed consent forms, and the study received ethical approval from China-Japan Friendship Hospital (No. 2019-42-K30).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All the data referred to in the manuscript are availability.
